| Literature DB >> 31535078 |
Rungkan Ruksasakul1, Pongthorn Narongroeknawin1, Paijit Assavatanabodee1, Sumapa Chaiamnuay1.
Abstract
BACKGROUND: Group B Streptococcus (GBS) emerged as the frequent pathogen for septic arthritis. There was no study comparing risks, clinical presentations and outcomes between GBS septic arthritis and other bacterial septic arthritis.The aim of this study is to evaluate the differences in risks, clinical presentations, and outcomes of GBS septic arthritis and other bacterial septic arthritis, and identify independent risks and clinical presentations suggesting GBS septic arthritis.Entities:
Keywords: Bacterial septic arthritis; Group B streptococcus; Oligoarthritis; Polyarthritis; Rainy season; Tenosynovitis
Year: 2019 PMID: 31535078 PMCID: PMC6745788 DOI: 10.1186/s41927-019-0084-5
Source DB: PubMed Journal: BMC Rheumatol ISSN: 2520-1026
Fig. 1The flowchart of the study
The demographics and clinical characteristics in GBS and other bacterial septic arthritis group
| Variable | All (231) | GBS group (87) | Other bacterial group (144) |
|
|---|---|---|---|---|
| Female (n, %) | 86, 37.2% | 36, 41.4% | 50, 34.7% | 0.311 |
| Age mean: (mean ± SD) | 60.8 + 17.3 | 58.6 + 16.1 | 62.2 + 18.0 | 0.136 |
| Body Mass Index: Median (IQR 25-IQR75) | 23.4 (20.8–25.8) | 23.0 (21.1–25.0) | 23.4 (20.8–26.4) | 0.608 |
| Season (n, %) | ||||
| Summer | 47, 20.3% | 11, 12.6% | 36, 25.0% | 0.024 |
| Rainy | 130, 56.3% | 62, 71.3% | 68, 47.2% | < 0.001 |
| Winter | 54, 23.4% | 14,16.1% | 40, 27.8% | 0.042 |
| Underlying disease (n, %) | 183, 79.2% | 58, 66.7% | 125, 86.8% | < 0.001 |
| Rheumatoid arthritis | 5, 2.2% | 1, 1.1% | 4, 2.8% | 0.653 |
| Diabetic mellitus | 71, 30.7% | 16, 18.4% | 55, 38.2% | 0.002 |
| ESRD (n, %) | 12, 5.2% | 2, 2.3% | 10, 6.9% | 0.219 |
| Liver disease | 30, 13.0% | 4, 4.6% | 26, 18.1% | 0.003 |
| Malignancy | 28, 12.1% | 9, 10.3% | 19, 13.2% | 0.520 |
| Hypertension | 110, 47.6% | 40, 46.0% | 70, 48.6% | 0.698 |
| Hyperlipidemia | 77, 33.3% | 30, 34.5% | 47, 32.6% | 0.773 |
| History of joint infection (n, %) | 7, 3.0% | 0, 0% | 7, 4.9% | 0.047 |
| History skin infection (n, %) | 30, 13.0% | 1, 1.1% | 29, 20.1% | < 0.001 |
| History of joint surgery (n, %) | 4, 1.7% | 1, 1.1% | 3, 2.1% | 1.000 |
| History of intraarticular steroid injection (n, %) | 7, 3.0% | 0, 0% | 7, 4.9% | 0.047 |
| Current medication (n, %) | ||||
| Prednisolone | 20, 8.7% | 4, 4.6% | 16, 11.1% | 0.088 |
| Chemotherapy | 8, 3.5% | 2, 2.3% | 6, 4.2% | 0.363 |
| Immunosuppressive drug | 9, 3.9% | 2, 2.3% | 7, 4.9% | 0.489 |
p < 0.05 defined statistical significance, IQR Interquartile range, ESRD End stage renal disease
Rainy season: 16 May – 15 October, Winter season:16 October – 13 February, Summer season:14 February – 15 May
The clinical presentations in GBS and other bacterial septic arthritis group
| Variable | All (231) | GBS group (87) | Other bacterial group (144) |
|
|---|---|---|---|---|
| Symptom duration: Median (IQR25-IQR75) | 5.0 (2.0–10.0) | 5.0 (2.0–10.0) | 4.0 (2.0–7.0) | 0.655 |
| Initial temperature: Median (IQR25-IQR75) | 37.8 (37.0–38.4) | 37.9 (37.2–38.5) | 37.8 (37.0–38.3) | 0.301 |
| Number of joint involvement: Median (IQR25-IQR75) | 1.0 (1.0–3.0) | 3.0 (1.0–5.0) | 1.0 (1.0–2.0) | < 0.001 |
| Pattern of joint involvement (n, %) | ||||
| Monoarthritis | 122, 52.8% | 24, 27.6% | 98, 68.1% | < 0.001 |
| Oligoarthritis | 58, 25.1% | 27, 31.0% | 31, 21.5% | 0.106 |
| Polyarthritis | 51, 22.1% | 36, 41.4% | 15, 10.4% | < 0.001 |
| Upper joint involvement | 113, 48.9% | 62, 71.3% | 51, 35.4% | < 0.001 |
| Axial joint involvement | 61, 26.4% | 33, 37.9% | 28, 19.4% | 0.002 |
| Small joint involvement | 22, 9.5% | 9, 10.3% | 13, 9.0% | 0.741 |
| Site of joint involvement (n, %) | ||||
| Knee | 146, 63.2% | 56, 64.4% | 90, 62.5% | 0.775 |
| Ankle | 59, 25.5% | 30, 34.5% | 29, 20.1% | 0.015 |
| Shoulder | 58, 25.1% | 29, 33.3% | 29, 20.1% | 0.025 |
| Wrist | 41, 17.7% | 27, 31.0% | 14, 9.7% | < 0.001 |
| Sternoclavicular | 28, 12.1% | 19, 21.8 | 9, 6.3% | < 0.001 |
| Elbow | 22, 9.5% | 15, 17.2% | 7, 4.9% | 0.002 |
| Spine | 17, 7.4% | 12, 13.8% | 5, 3.5% | 0.004 |
| Site of joint involvement (n, %) | ||||
| MCP | 13, 5.6% | 12, 13.8% | 1, 0.7% | < 0.001 |
| PIP | 14, 6.1% | 12, 13.8% | 2, 1.4% | < 0.001 |
| Hip | 25, 10.8% | 11, 12.6% | 14, 9.7% | 0.489 |
| AC | 13, 5.6% | 8, 9.2% | 5, 3.5% | 0.081 |
| MTP | 16, 6.9% | 8, 9.2% | 8, 5.6% | 0.291 |
| Interphalangeal of toe | 4, 1.7% | 4, 4.6% | 0, 0% | 0.019 |
| Sacroiliac | 5, 2.2% | 2, 2.3% | 3, 2.1% | 0.624 |
| Extra articular involvement (n, %) | ||||
| Tenosynovitis | 37, 16.0% | 34, 39.1% | 3, 2.08% | < 0.001 |
| CNS | 13, 5.7% | 9, 10.3% | 4, 2.8% | 0.035 |
| Skin involvement | 30, 13.0% | 6, 6.9% | 24, 16.7% | 0.032 |
| Tendon rupture | 5, 2.2% | 4, 4.6% | 1, 0.7% | 0.068 |
| Ocular involvement | 3, 1.3% | 3, 3.4% | 0, 0% | 0.052 |
| Cardiac involvement | 6, 2.6% | 1, 1.1% | 5, 3.5% | 0.414 |
| Concomitant infection (n, %) | 57, 24.7% | 4, 4.6% | 53, 36.8% | < 0.001 |
p < 0.05 defined statistical significance, IQR: Interquartile range, symptom duration: Duration from the onset of joint symptoms to the hospital admission, IQR Interquartile range, SC Sternoclavicular, MCP Metacarpophalangeal, PIP Proximal interphalangeal, AC Acromioclavicular, MTP Metatarsophalangeal, CNS Central nervous system, GBS Streptococcus group B
Upper joint included sternoclavicular joints, acromioclavicular joints, shoulder joints, elbow joints, wrist joints, metacarpophalangeal joints and proximal interphalangeal joints
Axial joint included sternoclavicular joints, acromioclavicular joints, shoulder joints, sacroiliac joint, hip joints and spine
Small joint included metacarpophalangeal joints, proximal interphalangeal joints, metatarsophalangeal joints,wrist and interphalangeal joints of toes
Multivariate analyses of factors associated with the GBS septic arthritis
| Parameter | All (231) | GBS group (87) | Other bacterial group (144) | Adjust odds | 95% CI | |
|---|---|---|---|---|---|---|
| Associated jointsa | ||||||
| MCP (n, %) | 13, 5.6% | 12, 13.8% | 1, 0.7% | 16.2 | 1.9–137.2 | 0.011 |
| PIP (n, %) | 14, 6.1% | 12, 13.8% | 2, 1.4% | 7.0 | 1.3–36.0 | 0.021 |
| Spine (n, %) | 17, 7.4% | 12, 13.8% | 5, 3.5% | 4.6 | 1.4–14.9 | 0.011 |
| SC (n, %) | 28, 12.1% | 19, 21.8% | 9, 6.3% | 3.2 | 1.2–8.2 | 0.017 |
| Associated factorsb | ||||||
| Tenosynovitis (n, %) | 37, 16.0% | 34, 39.08% | 3, 2.08% | 21.0 | 5.5–79.6 | < 0.001 |
| Rainy season (n, %) | 130, 56.3% | 62, 71.3% | 68, 47.2% | 3.6 | 1.8–7.5 | < 0.001 |
| Oligo-polyarthritis (n, %) | 109, 47.2% | 63, 72.4% | 46, 31.9% | 2.6 | 1.3–5.2 | 0.008 |
| Associated laboratory datac | ||||||
| Baseline hemoglobin (mg/dL): (mean ± SD) | 11.0 + 2.2 | 11.7 + 2.4 | 10.5 + 2.1 | 1.3 | 1.1–1.5 | < 0.001 |
p < 0.05 defined statistical significance,
GBS Streptococcus group B, MCP Metacarpophalangeal, PIP Proximal interphalangeal, SC Sternoclavicular
aAdjusted for knee, ankle, shoulder, wrist, SC, elbow, spine, MCP, PIP, hip, AC, MTP, IP of toe and SI joints
bAdjusted for age, gender, rainy season, body mass index, diabetic mellitus, end-stage renal disease, liver disease, oligo-polyarthritis, upper joint involvement, tenosynovitis, tendon rupture, ocular involvement and central nervous system involvement
cAdjusted for baseline serum WBC, hemoglobin, creatinine, hs-CRP, AST and ALT
The laboratory profiles in GBS and other bacterial septic arthritis group
| Variable | All (231) | GBS group (87) | Other bacterial group (144) |
|
|---|---|---|---|---|
| WBC in synovial fluid ( | 53,000.0 (25,200.0-110,720.0) | 54,000.0 (25,600.0-131,000.0) | 52,800.0 (24,030.0-106,000.0) | 0.640 |
| Hb (mg/dL): Mean ± SD | 11.0 + 2.2 | 11.7 + 2.4 | 10.5 + 2.1 | < 0.001 |
| Serum WBC ( | 13,400.0 (9500.0-18,800.0) | 15,000.0 (10,700.0-19,900.0) | 12,500.0 (8550.0-16,950.0) | 0.029 |
| BUN (mg/dL): Median (IQR25-IQR75) | 21.8 (13.8–39.6) | 18.4 (12.9–35.1) | 24.4 (14.5–43.6) | 0.040 |
| Cr (mg/dL): Median (IQR25-IQR75) | 1.0 (0.8–2.2) | 0.90 (0.8–1.5) | 1.20 (0.8–2.5) | 0.033 |
| AST (IU/L): Median (IQR25-IQR75) | 39.0 (26.5–69.8) | 37.0 (25.0–59.0) | 42.0 (27.0–71.0) | 0.182 |
| ALT (IU/L): Median (IQR25-IQR75) | 33.5 (20.0–55.5) | 35.0 (24.0–59.0) | 32.0 (17.0–54.0) | 0.175 |
| ESR (min/hr): Median (IQR25-IQR75) | 109.0 (86.0–119.0) | 104.5 (85.0–118.0) | 111.0 (86.0–119.0) | 0.558 |
| hs-CRP (mg/L): Median (IQR25-IQR75) | 185.2 (100.8–300.0) | 226.9 (142.2–300.0) | 157.0 (85.3–267.9) | 0.030 |
| Positive hemoculture (n, %) | 157, 68% | 62, 71.3% | 95, 66.0% | 0.404 |
| Positive synovial fluid culture (n, %) | 155, 67.1% | 55, 63.2% | 100, 69.4% | 0.329 |
p < 0.05 defined statistical significance, IQR Interquartile range, WBC White blood cell, Hb Hemoglobin, BUN Blood urea nitrogen, AST Aspartate aminotransferase, ALT Alanine Aminotransferase, ESR Erythrocyte sedimentation rate, hs-CRP High Sensitivity C-Reactive Protein, GBS Streptococcus group B
The treatment outcomes in GBS and other bacterial septic arthritis group
| Variable | All (231) | GBS group (87) | Other bacterial group (144) | |
|---|---|---|---|---|
| Surgery (n, %) | 134, 58.0% | 54, 62.1% | 80, 55.6% | 0.331 |
| Complication (n, %) | 132, 57.1% | 43, 49.4% | 89, 61.8% | 0.065 |
| Death (n, %) | 38, 16.5% | 5, 5.7% | 33, 22.9% | < 0.001 |
| Period of antibiotic treatment | ||||
| Total course (days): Median (IQR25-IQR75) | 57.0 (42.0–109.0) | 60.0 (42.0–143.0) | 56.0 (42.0–102.0) | 0.287 |
| Intravenous form (days): Median (IQR25-IQR75) | 29.0 (21.0–42.0) | 28.0 (19.0–37.0) | 30.0 (21.0–45.0) | 0.134 |
| Oral form (days): Median (IQR25-IQR75) | 30.0 (8.0–76.0) | 34.5 (17.0–98.0) | 28.0 (0.0–60.0) | 0.007 |
| Length of stay (days): Median (IQR25-IQR75) | 29.0 (18.0–42.0) | 27.0 (19.0–38.0) | 31.0 (18.0–47.0) | 0.378 |
p < 0.05 defined statistical significance, IQR Interquartile range, GBS Streptococcus group B. Complications included sepsis, shock, intubation, admit to intensive unit care, pneumonia, upper urinary tract infection, pressure sore and osteomyelitis
The demographics and clinical characteristics in death and survived patients and factor associated with death
| Variable (n, %) | All ( | Univariate analyses | Multivariate analysesa | |||
|---|---|---|---|---|---|---|
| Death ( | Survived ( | Adjusted Odd ratio (95% confidence interval) | ||||
| Underlying disease | 183, 79.2% | 35, 92.1% | 148, 76.7% | .030 | 1.01 (0.23–4.51) | 0. 981 |
| End staged renal disease | 12, 5.2% | 5, 13.2% | 7, 3.6% | .031 | 3.53 (0.91–13.73) | 0.069 |
| Hypertension | 110, 47.6% | 26, 68.4% | 84, 43.5% | .007 | 2.63 (1.12–5.86) | 0.047 |
| Axial joint involvement | 61, 26.4% | 5, 13.2% | 56, 29.0% | .045 | 0.45 (0.16–1.32) | 0.156 |
| Concomitant infection | 57, 24.7% | 15, 39.5% | 42, 21.8% | .025 | 1.57 (0.67–3.69) | 0.343 |
| Positive synovial fluid culture | 155, 67.1% | 33, 86.8% | 122, 63.2% | 0.004 | 5.67 (1.94–16.58) | 0.002 |
| Positive hemoculture | 157, 68.0% | 30, 80.0% | 127, 65.8% | 0.130 | 2.95 (1.18–7.38) | 0.020 |
| Group B streptococcus | 87, 37.7% | 5, 5.7% | 82, 94.3% | < 0.001 | 0.21 (0.07–0.59) | 0.003 |
|
| 54, 23.4% | 17, 31.5% | 37, 68.5% | 0.001 | 1.34 (0.55–3.29) | 0.515 |
aadjusted for age, sex, Group B streptococcus, Staphylococcus aureus group, Underlying disease, Hypertension, End stage renal disease, axial joint involvement, concomitant infection, positive synovial fluid culture and positive hemoculture